Healthcare provider profile · identity verified

Mario A Lanza, MD

Family Practice · NEWTON, KS · NPI 1790756856

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	697	221
Amlodipine Besylate	Amlodipine Besylate	337	117
Lisinopril	Lisinopril	325	114
Levothyroxine Sodium	Levothyroxine Sodium	311	86
Atorvastatin Calcium	Atorvastatin Calcium	232	77
Omeprazole	Omeprazole	228	76
Metformin Hcl Er	Metformin Hcl	199	52
Meloxicam	Meloxicam	182	68
Jardiance	Empagliflozin	176	51
Losartan Potassium	Losartan Potassium	163	57
Pantoprazole Sodium	Pantoprazole Sodium	157	41
Tamsulosin Hcl	Tamsulosin Hcl	152	44
Metoprolol Succinate	Metoprolol Succinate	149	49
Gabapentin	Gabapentin	134	38
Duloxetine Hcl	Duloxetine Hcl	119	37
Allopurinol	Allopurinol	106	28
Metformin Hcl	Metformin Hcl	104	31
Alendronate Sodium	Alendronate Sodium	93	35
Furosemide	Furosemide	91	28
Xarelto	Rivaroxaban	90	27
Potassium Chloride	Potassium Chloride	84	28
Shingrix	Varicella-Zoster Ge/As01b/Pf	76	67
Sertraline Hcl	Sertraline Hcl	74	16
Hydrochlorothiazide	Hydrochlorothiazide	60	19
Carvedilol	Carvedilol	59	21
Clopidogrel	Clopidogrel Bisulfate	57	20
Famotidine	Famotidine	54	14
Albuterol Sulfate Hfa	Albuterol Sulfate	52	19
Fluticasone Propionate	Fluticasone Propionate	51	18
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	45	16
Eliquis	Apixaban	43	20
Symbicort	Budesonide/Formoterol Fumarate	43	17
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	40	13
Escitalopram Oxalate	Escitalopram Oxalate	38	11
Finasteride	Finasteride	36	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	36	33
Trazodone Hcl	Trazodone Hcl	35	11
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	34	34
Pioglitazone Hcl	Pioglitazone Hcl	32	suppressed
Spironolactone	Spironolactone	30	suppressed
Celecoxib	Celecoxib	29	suppressed
Ozempic	Semaglutide	27	suppressed
Tramadol Hcl	Tramadol Hcl	27	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	26	26
Metoprolol Tartrate	Metoprolol Tartrate	26	12
Triamcinolone Acetonide	Triamcinolone Acetonide	26	16
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	25	23
Citalopram Hbr	Citalopram Hydrobromide	25	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	25	suppressed
Tizanidine Hcl	Tizanidine Hcl	24	15
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	24	suppressed
Chlorthalidone	Chlorthalidone	23	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	22	suppressed
Montelukast Sodium	Montelukast Sodium	22	suppressed
Benazepril Hcl	Benazepril Hcl	21	suppressed
Bupropion Xl	Bupropion Hcl	21	suppressed
Alprazolam	Alprazolam	20	suppressed
Bumetanide	Bumetanide	20	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	19	suppressed
Baclofen	Baclofen	18	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Gemtesa	Vibegron	18	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	18	suppressed
Levemir Flexpen	Insulin Detemir	18	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Novolog Penfill	Insulin Aspart	18	suppressed
Oxycodone Hcl	Oxycodone Hcl	18	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Primidone	Primidone	17	suppressed
Simvastatin	Simvastatin	17	suppressed
Buspirone Hcl	Buspirone Hcl	16	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	16	suppressed
Labetalol Hcl	Labetalol Hcl	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Propranolol Hcl Er	Propranolol Hcl	16	suppressed
Valacyclovir	Valacyclovir Hcl	16	suppressed
Dexlansoprazole Dr	Dexlansoprazole	14	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Novolog Flexpen	Insulin Aspart	14	suppressed
Sotalol	Sotalol Hcl	14	suppressed
Aripiprazole	Aripiprazole	13	suppressed
Dutasteride	Dutasteride	13	suppressed
Naratriptan Hcl	Naratriptan Hcl	13	suppressed
Telmisartan	Telmisartan	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Atenolol	Atenolol	12	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Naproxen	Naproxen	12	suppressed
Oxcarbazepine	Oxcarbazepine	12	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error